Stocktoria
Surrozen, Inc./DE SRZN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-11-23
Surrozen, Inc./DE statistics & valuation
Market cap$292.8M
P / S84.2×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -1210.6% | -239.7% | — | -354.7% | — |
| Net margin | -6960.8% | -596.6% | — | -288.0% | — |
| FCF margin | -873.5% | -165.7% | — | -359.0% | — |
| Return on assets | -245.1% | -131.1% | -93.4% | -40.3% | -39.8% |
| Return on equity | 128.9% | 297.3% | -113.5% | -47.4% | -49.8% |
| Current ratio | 9.22 | 5.32 | 5.75 | 8.35 | 7.75 |
| Revenue growth | -67.4% | — | -100.0% | — | — |
Source: SEC EDGAR filings · CIK 0001824893 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.